Guoqiao Zheng1, Jan Sundquist2,3,4, Kristina Sundquist2,3,4, Jianguang Ji2. 1. Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden. guoqiao.zheng@med.lu.se. 2. Center for Primary Health Care Research, Lund University/Region Skåne, Malmö, Sweden. 3. Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Center for Community-based Healthcare Research and Education (CoHRE), Department of Functional Pathology, School of Medicine, Shimane University, Shimane, Japan.
Abstract
BACKGROUND: Expensive cancer treatment calls for alternative ways such as drug repurposing to develop effective drugs. The aim of this study was to analyse the effect of post-diagnostic use of cholera vaccine on survival outcome in breast cancer patients. METHODS: Cancer diagnosis and cholera vaccination were obtained by linkage of several Swedish national registries. One vaccinated patient was matched with maximum two unvaccinated individuals based on demographic, clinical and socioeconomic factors. We performed proportional Cox regression model to analyse the differences in overall and disease-specific survivals between the matched patients. RESULTS: In total, 617 patients received cholera vaccine after breast cancer diagnosis. The median (interquartile range) time from diagnosis to vaccination was 30 (15-51) months and from vaccination to the end of follow-up it was 62 (47-85) months. Among them, 603 patients were matched with 1194 unvaccinated patients. Vaccinated patients showed favourable overall survival (hazard ratio (HR): 0.54, 95% confidence interval (CI): 0.37-0.79) and disease-specific survival (HR: 0.53, 95% CI: 0.33-0.84), compared to their unvaccinated counterpart. The results were still significant in multiple sensitivity analyses. CONCLUSIONS: Post-diagnostic use of cholera vaccine is associated with a favourable survival rate in breast cancer patients; this provides evidence for repurposing it against breast cancer.
BACKGROUND: Expensive cancer treatment calls for alternative ways such as drug repurposing to develop effective drugs. The aim of this study was to analyse the effect of post-diagnostic use of cholera vaccine on survival outcome in breast cancerpatients. METHODS:Cancer diagnosis and cholera vaccination were obtained by linkage of several Swedish national registries. One vaccinated patient was matched with maximum two unvaccinated individuals based on demographic, clinical and socioeconomic factors. We performed proportional Cox regression model to analyse the differences in overall and disease-specific survivals between the matched patients. RESULTS: In total, 617 patients received cholera vaccine after breast cancer diagnosis. The median (interquartile range) time from diagnosis to vaccination was 30 (15-51) months and from vaccination to the end of follow-up it was 62 (47-85) months. Among them, 603 patients were matched with 1194 unvaccinated patients. Vaccinated patients showed favourable overall survival (hazard ratio (HR): 0.54, 95% confidence interval (CI): 0.37-0.79) and disease-specific survival (HR: 0.53, 95% CI: 0.33-0.84), compared to their unvaccinated counterpart. The results were still significant in multiple sensitivity analyses. CONCLUSIONS: Post-diagnostic use of cholera vaccine is associated with a favourable survival rate in breast cancerpatients; this provides evidence for repurposing it against breast cancer.
Authors: Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali Journal: Med Care Date: 2005-11 Impact factor: 2.983
Authors: Ed C Lavelle; Andrew Jarnicki; Edel McNeela; Michelle E Armstrong; Sarah C Higgins; Olive Leavy; Kingston H G Mills Journal: J Leukoc Biol Date: 2004-01-02 Impact factor: 4.962
Authors: Scott D Ramsey; Aasthaa Bansal; Catherine R Fedorenko; David K Blough; Karen A Overstreet; Veena Shankaran; Polly Newcomb Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Mehdi Nikbakht Dastjerdi; Mohammad R Salahshoor; Mohammad Mardani; Batool Hashemibeni; Shiva Roshankhah Journal: Adv Biomed Res Date: 2013-03-06
Authors: Jenna H Newman; C Brent Chesson; Nora L Herzog; Praveen K Bommareddy; Salvatore M Aspromonte; Russell Pepe; Ricardo Estupinian; Mones M Aboelatta; Stuti Buddhadev; Saeed Tarabichi; Michael Lee; Shengguo Li; Daniel J Medina; Eileena F Giurini; Kajal H Gupta; Gabriel Guevara-Aleman; Marco Rossi; Christina Nowicki; Abdulkareem Abed; Josef W Goldufsky; Joseph R Broucek; Raquel E Redondo; David Rotter; Sachin R Jhawar; Shang-Jui Wang; Frederick J Kohlhapp; Howard L Kaufman; Paul G Thomas; Vineet Gupta; Timothy M Kuzel; Jochen Reiser; Joyce Paras; Michael P Kane; Eric A Singer; Jyoti Malhotra; Lisa K Denzin; Derek B Sant'Angelo; Arnold B Rabson; Leonard Y Lee; Ahmed Lasfar; John Langenfeld; Jason M Schenkel; Mary Jo Fidler; Emily S Ruiz; Amanda L Marzo; Jai S Rudra; Ann W Silk; Andrew Zloza Journal: Proc Natl Acad Sci U S A Date: 2019-12-30 Impact factor: 11.205